Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Long term observation of MRSA prevalence in a German rehabilitation center: risk factors and variability of colonization rate.

Gieffers J, Ahuja A, Giemulla R.

GMS Hyg Infect Control. 2016 Oct 5;11:Doc21. eCollection 2016.

2.

Impact of a low-oxygen environment on the efficacy of antimicrobials against intracellular Chlamydia trachomatis.

Shima K, Szaszák M, Solbach W, Gieffers J, Rupp J.

Antimicrob Agents Chemother. 2011 May;55(5):2319-24. doi: 10.1128/AAC.01655-10. Epub 2011 Feb 14.

3.

Variation in the mutation frequency determining quinolone resistance in Chlamydia trachomatis serovars L2 and D.

Rupp J, Solbach W, Gieffers J.

J Antimicrob Chemother. 2008 Jan;61(1):91-4. Epub 2007 Nov 22.

PMID:
18033786
4.
5.

Prevalence, genetic conservation and transmissibility of the Chlamydia pneumoniae bacteriophage (phiCpn1).

Rupp J, Solbach W, Gieffers J.

FEMS Microbiol Lett. 2007 Aug;273(1):45-9. Epub 2007 Jun 6.

6.

Chlamydia pneumoniae directly interferes with HIF-1alpha stabilization in human host cells.

Rupp J, Gieffers J, Klinger M, van Zandbergen G, Wrase R, Maass M, Solbach W, Deiwick J, Hellwig-Burgel T.

Cell Microbiol. 2007 Sep;9(9):2181-91. Epub 2007 May 8.

PMID:
17490410
7.

Recurrent optic neuritis associated with Chlamydia pneumoniae infection of the central nervous system.

Pohl D, Rostasy K, Gieffers J, Maass M, Hanefeld F.

Dev Med Child Neurol. 2006 Sep;48(9):770-2.

8.

Be aware of the possibility of false-positive results in single-locus PCR assays for methicillin-resistant Staphylococcus aureus.

Rupp J, Fenner I, Solbach W, Gieffers J.

J Clin Microbiol. 2006 Jun;44(6):2317. No abstract available.

10.

Growth cycle-dependent pharmacodynamics of antichlamydial drugs.

Siewert K, Rupp J, Klinger M, Solbach W, Gieffers J.

Antimicrob Agents Chemother. 2005 May;49(5):1852-6.

11.

Cox-2 inhibition abrogates Chlamydia pneumoniae-induced PGE2 and MMP-1 expression.

Rupp J, Berger M, Reiling N, Gieffers J, Lindschau C, Haller H, Dalhoff K, Maass M.

Biochem Biophys Res Commun. 2004 Jul 30;320(3):738-44.

PMID:
15240110
12.

Phagocytes transmit Chlamydia pneumoniae from the lungs to the vasculature.

Gieffers J, van Zandbergen G, Rupp J, Sayk F, Krüger S, Ehlers S, Solbach W, Maass M.

Eur Respir J. 2004 Apr;23(4):506-10.

13.

First-choice antibiotics at subinhibitory concentrations induce persistence of Chlamydia pneumoniae.

Gieffers J, Rupp J, Gebert A, Solbach W, Klinger M.

Antimicrob Agents Chemother. 2004 Apr;48(4):1402-5.

14.

Chlamydia pneumoniae multiply in neutrophil granulocytes and delay their spontaneous apoptosis.

van Zandbergen G, Gieffers J, Kothe H, Rupp J, Bollinger A, Aga E, Klinger M, Brade H, Dalhoff K, Maass M, Solbach W, Laskay T.

J Immunol. 2004 Feb 1;172(3):1768-76.

15.

Chlamydia pneumoniae and atherosclerosis.

Belland RJ, Ouellette SP, Gieffers J, Byrne GI.

Cell Microbiol. 2004 Feb;6(2):117-27. Review.

PMID:
14706098
16.

Genotypic differences in the Chlamydia pneumoniae tyrP locus related to vascular tropism and pathogenicity.

Gieffers J, Durling L, Ouellette SP, Rupp J, Maass M, Byrne GI, Caldwell HD, Belland RJ.

J Infect Dis. 2003 Oct 15;188(8):1085-93. Epub 2003 Oct 10.

PMID:
14551876
17.

Micromanipulation of the Chlamydia pneumoniae inclusion: implications for cloning and host-pathogen interactions.

Gieffers J, Tamplin V, Maass M, Belland RJ, Caldwell HD.

FEMS Microbiol Lett. 2003 Sep 12;226(1):45-9.

18.

Hydroxymethylglutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae-induced cell interaction and activation.

Dechend R, Gieffers J, Dietz R, Joerres A, Rupp J, Luft FC, Maass M.

Circulation. 2003 Jul 22;108(3):261-5. Epub 2003 Jul 14.

PMID:
12860900
19.

Isolation of Chlamydia pneumoniae clonal variants by a focus-forming assay.

Gieffers J, Belland RJ, Whitmire W, Ouellette S, Crane D, Maass M, Byrne GI, Caldwell HD.

Infect Immun. 2002 Oct;70(10):5827-34.

20.
21.

Presence of Chlamydia pneumoniae DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis.

Gieffers J, Pohl D, Treib J, Dittmann R, Stephan C, Klotz K, Hanefeld F, Solbach W, Haass A, Maass M.

Ann Neurol. 2001 May;49(5):585-9.

PMID:
11357948
22.

Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment.

Gieffers J, Füllgraf H, Jahn J, Klinger M, Dalhoff K, Katus HA, Solbach W, Maass M.

Circulation. 2001 Jan 23;103(3):351-6.

PMID:
11157684
23.

Cardiovascular infection by Chlamydia pneumoniae is not related to apolipoprotein E genotype.

Gieffers J, Solbach W, Maass M.

Clin Infect Dis. 2000 Dec;31(6):1515-6.

PMID:
11096027
24.

Detection of Chlamydia pneumoniae within peripheral blood monocytes of patients with unstable angina or myocardial infarction.

Maass M, Jahn J, Gieffers J, Dalhoff K, Katus HA, Solbach W.

J Infect Dis. 2000 Jun;181 Suppl 3:S449-51.

PMID:
10839736
25.

Atherogenetically relevant cells support continuous growth of Chlamydia pneumoniae.

Maass M, Gieffers J, Solbach W.

Herz. 2000 Mar;25(2):68-72.

PMID:
10829241
26.

Failure to detect Chlamydia pneumoniae in brain sections of Alzheimer's disease patients.

Gieffers J, Reusche E, Solbach W, Maass M.

J Clin Microbiol. 2000 Feb;38(2):881-2.

27.
28.
29.

In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries.

Gieffers J, Solbach W, Maass M.

Antimicrob Agents Chemother. 1998 Oct;42(10):2762-4.

Supplemental Content

Loading ...
Support Center